Glenmark’s Coup: Gilead’s Riva Now CEO Of Spin-Out Innovation Firm
Glenmark has snagged a top name in oncology from Gilead to lead its spin-out innovation business.
You may also be interested in...
After several staff departures, Gilead consolidates its research arm under CEO oversight, while welcoming another Roche/Genentech alum.
FDA orphan drug designation for Glenmark’s multiple myeloma candidate is seen as an important milestone ahead of its innovation spin out’s plans to raise capital in the US to fund pipeline development.
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.